Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pregnancy Complications, Cardiovascular | 10 | 2019 | 231 | 3.74 | Why? |
| Cardiomyopathies | 13 | 2019 | 997 | 2.88 | Why? |
| Peripartum Period | 9 | 2019 | 89 | 2.31 | Why? |
| Rheumatic Heart Disease | 6 | 2018 | 44 | 2.01 | Why? |
| Puerperal Disorders | 6 | 2019 | 151 | 1.88 | Why? |
| Heart Failure | 13 | 2021 | 6638 | 1.15 | Why? |
| Cardiovascular Diseases | 15 | 2021 | 11497 | 1.02 | Why? |
| Bromocriptine | 5 | 2018 | 42 | 0.88 | Why? |
| Ventricular Function, Left | 4 | 2018 | 1555 | 0.88 | Why? |
| Developing Countries | 8 | 2020 | 4283 | 0.81 | Why? |
| Arterial Pressure | 2 | 2018 | 208 | 0.80 | Why? |
| Hypertension, Pulmonary | 3 | 2018 | 970 | 0.79 | Why? |
| Poverty | 3 | 2020 | 2302 | 0.79 | Why? |
| Rheumatic Fever | 1 | 2018 | 36 | 0.76 | Why? |
| Maternal Death | 1 | 2018 | 108 | 0.66 | Why? |
| Placenta Growth Factor | 1 | 2017 | 93 | 0.65 | Why? |
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2017 | 120 | 0.64 | Why? |
| Pulmonary Artery | 2 | 2018 | 803 | 0.56 | Why? |
| Heart Conduction System | 1 | 2017 | 266 | 0.55 | Why? |
| Cardiology | 6 | 2021 | 2873 | 0.52 | Why? |
| Heart Valve Diseases | 1 | 2018 | 355 | 0.52 | Why? |
| Neovascularization, Pathologic | 1 | 2017 | 305 | 0.51 | Why? |
| Cardiovascular Agents | 2 | 2017 | 663 | 0.51 | Why? |
| Observational Studies as Topic | 1 | 2021 | 1887 | 0.50 | Why? |
| Stroke Volume | 3 | 2019 | 2153 | 0.50 | Why? |
| Hormone Antagonists | 2 | 2018 | 29 | 0.47 | Why? |
| Africa South of the Sahara | 6 | 2019 | 1335 | 0.45 | Why? |
| Decision Support Techniques | 1 | 2018 | 903 | 0.44 | Why? |
| Ventricular Dysfunction, Left | 2 | 2018 | 993 | 0.43 | Why? |
| Noncommunicable Diseases | 1 | 2020 | 934 | 0.43 | Why? |
| Pregnancy Outcome | 5 | 2019 | 3803 | 0.42 | Why? |
| Global Health | 8 | 2021 | 13911 | 0.40 | Why? |
| Electrocardiography | 3 | 2019 | 3957 | 0.39 | Why? |
| Perindopril | 2 | 2019 | 11 | 0.39 | Why? |
| Hydrochlorothiazide | 2 | 2019 | 31 | 0.38 | Why? |
| Amlodipine | 2 | 2019 | 45 | 0.37 | Why? |
| Heart Ventricles | 2 | 2018 | 1139 | 0.37 | Why? |
| Cardiac Surgical Procedures | 6 | 2018 | 1931 | 0.37 | Why? |
| Morbidity | 4 | 2019 | 1426 | 0.37 | Why? |
| Africa | 5 | 2021 | 2986 | 0.36 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.36 | Why? |
| Societies, Medical | 4 | 2021 | 6907 | 0.36 | Why? |
| Patient Care Management | 1 | 2019 | 1514 | 0.35 | Why? |
| Arrhythmias, Cardiac | 2 | 2021 | 2510 | 0.34 | Why? |
| Wounds and Injuries | 1 | 2020 | 1708 | 0.34 | Why? |
| Echocardiography | 3 | 2019 | 3661 | 0.33 | Why? |
| Pregnancy | 12 | 2019 | 23879 | 0.31 | Why? |
| Disease Management | 3 | 2019 | 6841 | 0.30 | Why? |
| World Health Organization | 1 | 2018 | 4213 | 0.30 | Why? |
| South Africa | 6 | 2018 | 3326 | 0.29 | Why? |
| Hypertension | 7 | 2020 | 8895 | 0.28 | Why? |
| Ventricular Function, Right | 2 | 2018 | 388 | 0.27 | Why? |
| Prognosis | 8 | 2021 | 32490 | 0.26 | Why? |
| Atrial Fibrillation | 1 | 2018 | 2320 | 0.26 | Why? |
| Air Pollution | 4 | 2021 | 3504 | 0.23 | Why? |
| American Heart Association | 2 | 2021 | 347 | 0.23 | Why? |
| Antihypertensive Agents | 3 | 2019 | 1962 | 0.23 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.22 | Why? |
| Europe | 6 | 2021 | 12702 | 0.21 | Why? |
| Thoracic Surgery | 2 | 2018 | 623 | 0.21 | Why? |
| Health Policy | 1 | 2020 | 6242 | 0.20 | Why? |
| Gross Domestic Product | 1 | 2021 | 134 | 0.20 | Why? |
| Risk Factors | 12 | 2021 | 71621 | 0.20 | Why? |
| Acute Disease | 4 | 2021 | 6029 | 0.20 | Why? |
| Heart Diseases | 2 | 2018 | 3503 | 0.19 | Why? |
| Socioeconomic Factors | 5 | 2021 | 8495 | 0.19 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.19 | Why? |
| Decision Trees | 1 | 2020 | 441 | 0.18 | Why? |
| Survival Rate | 3 | 2017 | 9206 | 0.18 | Why? |
| Predictive Value of Tests | 3 | 2018 | 9537 | 0.18 | Why? |
| Registries | 4 | 2019 | 12327 | 0.18 | Why? |
| Humans | 47 | 2021 | 930598 | 0.17 | Why? |
| Blood Pressure | 4 | 2019 | 2198 | 0.17 | Why? |
| Parvovirus B19, Human | 1 | 2017 | 73 | 0.17 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.16 | Why? |
| Health Resources | 2 | 2021 | 2592 | 0.16 | Why? |
| Echocardiography, Doppler | 1 | 2018 | 269 | 0.16 | Why? |
| Biomechanical Phenomena | 1 | 2017 | 291 | 0.16 | Why? |
| Myocardial Contraction | 1 | 2017 | 123 | 0.16 | Why? |
| Cell-Derived Microparticles | 1 | 2017 | 134 | 0.15 | Why? |
| Female | 25 | 2019 | 380317 | 0.15 | Why? |
| Action Potentials | 1 | 2017 | 368 | 0.15 | Why? |
| Economic Recession | 1 | 2021 | 453 | 0.15 | Why? |
| Parvoviridae Infections | 1 | 2017 | 222 | 0.15 | Why? |
| Delivery of Health Care | 2 | 2021 | 15909 | 0.14 | Why? |
| Follow-Up Studies | 6 | 2019 | 17020 | 0.14 | Why? |
| Adrenergic beta-Antagonists | 1 | 2018 | 465 | 0.14 | Why? |
| Contraception | 1 | 2018 | 291 | 0.14 | Why? |
| Takotsubo Cardiomyopathy | 1 | 2021 | 453 | 0.14 | Why? |
| Cardiotonic Agents | 1 | 2017 | 418 | 0.14 | Why? |
| Forecasting | 2 | 2019 | 4492 | 0.13 | Why? |
| Myocardial Ischemia | 1 | 2021 | 781 | 0.13 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.13 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.13 | Why? |
| Myocarditis | 2 | 2021 | 2731 | 0.13 | Why? |
| Scotland | 1 | 2017 | 1119 | 0.12 | Why? |
| Pilot Projects | 2 | 2018 | 5182 | 0.12 | Why? |
| Infant, Newborn | 5 | 2019 | 23105 | 0.12 | Why? |
| Cardiovascular System | 1 | 2020 | 750 | 0.12 | Why? |
| Prospective Studies | 6 | 2019 | 43301 | 0.11 | Why? |
| Cardiac Catheterization | 1 | 2018 | 882 | 0.11 | Why? |
| Ventricular Dysfunction, Right | 1 | 2018 | 639 | 0.11 | Why? |
| International Cooperation | 3 | 2021 | 3436 | 0.11 | Why? |
| Cathepsin D | 1 | 2010 | 8 | 0.11 | Why? |
| Switzerland | 1 | 2018 | 2738 | 0.11 | Why? |
| Single-Blind Method | 3 | 2019 | 1283 | 0.10 | Why? |
| Health Services Accessibility | 3 | 2018 | 10697 | 0.10 | Why? |
| Prolactin | 1 | 2010 | 68 | 0.10 | Why? |
| Demography | 1 | 2017 | 1660 | 0.10 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.10 | Why? |
| Health Expenditures | 1 | 2017 | 904 | 0.09 | Why? |
| Patient Readmission | 1 | 2018 | 1543 | 0.09 | Why? |
| Antimalarials | 1 | 2021 | 2505 | 0.09 | Why? |
| Internationality | 2 | 2018 | 3297 | 0.09 | Why? |
| Coronavirus Infections | 4 | 2021 | 253789 | 0.09 | Why? |
| Ramipril | 2 | 2019 | 81 | 0.09 | Why? |
| Risk Assessment | 4 | 2020 | 25439 | 0.09 | Why? |
| Urban Health | 1 | 2011 | 382 | 0.09 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.08 | Why? |
| Congresses as Topic | 1 | 2017 | 1347 | 0.08 | Why? |
| Acute Coronary Syndrome | 1 | 2021 | 2107 | 0.08 | Why? |
| Adult | 12 | 2019 | 244371 | 0.08 | Why? |
| Air Pollutants | 2 | 2021 | 3110 | 0.08 | Why? |
| Delivery of Health Care, Integrated | 1 | 2018 | 1549 | 0.08 | Why? |
| Incidence | 3 | 2017 | 25622 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.08 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.08 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 952 | 0.08 | Why? |
| Chloroquine | 1 | 2021 | 3152 | 0.08 | Why? |
| HIV Infections | 1 | 2011 | 11620 | 0.07 | Why? |
| Parturition | 1 | 2010 | 514 | 0.07 | Why? |
| Male | 12 | 2019 | 367725 | 0.07 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.07 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.07 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.07 | Why? |
| Middle Aged | 10 | 2019 | 270681 | 0.06 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.06 | Why? |
| Radiography, Thoracic | 1 | 2018 | 5486 | 0.06 | Why? |
| Germany | 1 | 2017 | 9196 | 0.06 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.06 | Why? |
| Cooperative Behavior | 2 | 2018 | 1216 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.05 | Why? |
| Endocrine System | 1 | 2019 | 67 | 0.05 | Why? |
| Models, Statistical | 1 | 2017 | 5312 | 0.05 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.05 | Why? |
| Diastole | 1 | 2019 | 168 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Drug Combinations | 2 | 2019 | 3852 | 0.05 | Why? |
| Systole | 1 | 2019 | 252 | 0.05 | Why? |
| Environmental Health | 1 | 2021 | 203 | 0.04 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2021 | 9044 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2021 | 12361 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Diabetes Mellitus | 1 | 2019 | 8207 | 0.04 | Why? |
| Thromboembolism | 1 | 2010 | 2101 | 0.04 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.04 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.04 | Why? |
| Cameroon | 1 | 2017 | 464 | 0.04 | Why? |
| Maternal Mortality | 1 | 2019 | 461 | 0.04 | Why? |
| Blood Pressure Determination | 1 | 2019 | 450 | 0.04 | Why? |
| Treatment Outcome | 4 | 2018 | 51732 | 0.04 | Why? |
| Stakeholder Participation | 1 | 2018 | 481 | 0.04 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 520 | 0.03 | Why? |
| Ultrasonography | 1 | 2010 | 4409 | 0.03 | Why? |
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 669 | 0.03 | Why? |
| Peripheral Arterial Disease | 1 | 2019 | 471 | 0.03 | Why? |
| Aged | 6 | 2019 | 215776 | 0.03 | Why? |
| Myocardial Infarction | 2 | 2019 | 3361 | 0.03 | Why? |
| Postpartum Period | 1 | 2019 | 936 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.03 | Why? |
| Epidemics | 1 | 2011 | 6407 | 0.03 | Why? |
| Denmark | 1 | 2018 | 2654 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2017 | 2739 | 0.02 | Why? |
| Young Adult | 2 | 2011 | 93724 | 0.02 | Why? |
| Oxidative Stress | 1 | 2021 | 2050 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Particulate Matter | 1 | 2021 | 3249 | 0.02 | Why? |
| Recovery of Function | 1 | 2017 | 2461 | 0.02 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.02 | Why? |
| Stroke | 2 | 2019 | 8839 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Logistic Models | 1 | 2019 | 9089 | 0.02 | Why? |
| United States | 2 | 2021 | 46150 | 0.02 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.01 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 5277 | 0.01 | Why? |
| Adolescent | 1 | 2010 | 86841 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Retrospective Studies | 2 | 2019 | 105322 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |